RxDoctor Payments Data

David McKenzie

Foot & Ankle Surgery · Tooele, UTNPI 1245541937

Payments from drug & device makers

What this record shows

31 manufacturers reported payments, led by Stryker at 58.1% of the total. Reporting peaked in 2019 at $4,271 and has fallen 75.6% since, to $1,043 in 2025.

$7,570in general payments, 2019–2025

Across 135 payments — averaging $56.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$4K
  • Paragon 28, Inc.$1K
  • Boston Scientific$210
  • Celularity Inc.$178
  • Sanara Medtech Inc.$166
  • Orthofix Medical, Inc.$148
  • plus $1K from 25 others

What the payments were for

  • Travel & lodging$3,51246%
  • Food & beverage$4,05954%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,570 in reported general payments places this provider in the 70th percentile of 104 foot & ankle surgery providers in Utah.

See all foot & ankle surgery providers in Utah

Medicare billing

Part B allowed, 2024
$253,772
Medicare patients
292
Services billed
2,675

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JubliaEfinaconazole20$16,284
Linezolid17$3,171
Gabapentin33$959
Doxycycline Monohydrate21$325
Pregabalin14$292
Cephalexin46$288
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen37$264
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip11$256
Methylprednisolone21$180
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen16$153
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav11$124
Acetaminophen-CodeineAcetaminophen With Codeine14$76
Levofloxacin24$60

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$41$16,28420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 104 foot & ankle surgery providers in Utah.

Other foot & ankle surgery in Tooele

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →